Nexium Patent Battle Could Switch To Generic Vs. Generic Fight
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva obtains a license from AstraZeneca to begin marketing generic Nexium in May 2014 but may be delayed by Ranbaxy's exclusivity; Teva also withdraws appeal of ruling that upheld Merck's Singulair patent.